Citi Retains Sell on Aurobindo Pharma, Raises Target Price

📉

continues to receive a 'Sell' rating from Citigroup, which has raised its target price to ₹1,270 from ₹1,020. The brokerage cited elevated valuations, with the stock trading around two standard deviations above historical averages, and highlighted limited visibility on the future product pipeline.